IMMUPHARMA PLC | Regulatory Story | |||
| Go to market news section | |||
|
ImmuPharma PLC
('ImmuPharma' or the 'Company')
Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that the NEX Exchange Growth Market ('NEX') has today released a pre-admission announcement under Rule 23 of the intention of Incanthera plc ('Incanthera'), a specialist oncology company, to quote on NEX.
ImmuPharma currently holds a 14.0% shareholding in Incantherafollowing its subscription for shares in September 2018. Following admission, ImmuPharma will retain 7,272,740 shares in Incanthera, representing 11.9%.
At the time of the subscription, ImmuPharma was also granted warrants to subscribe for additional ordinary shares in Incanthera at any time over five years from the initial subscription. These warrants have been carried over into the new listed plc company and now total 7,272,740 warrants. The exercise price has been rebased to the issue price.
Commenting on the announcement, Dimitri Dimitrou, CEO of ImmuPharma said:
'We are delighted to note Incanthera's imminent quote on NEX.
'Incanthera's diverse oncology pipeline has blockbuster potential. We are confident of the medium to long term prospects of the business, but we are particularly excited at the potential near term commercialisation of the lead product Sol, for skin cancer and other topical indications.
'As a major shareholder, with a tangible stake in the future success of Incanthera, we look forward to the creation of further value for our shareholders as Incanthera moves forward'.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ('MAR').
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, LupuzorTM, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visitwww.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Incanthera Limited
Incanthera Limited was formed in 2010 as a spin-out from the Institute of Cancer Therapeutics at Bradford University and is targeting the treatment of cancer through a portfolio of unique technologies. Having successfully commercialised its lead product in 2017, it is actively acquiring and developing technologies to further enhance its portfolio of cancer therapeutics. For more information, please visitwww.incanthera.com
About NEX
NEX Exchange (formerly known as ISDX) is the ICAP Securities and Derivatives Exchange. The NEX Exchange Growth Market is an equity market for small and medium-sized ambitious, growth enterprises. Typically its admission requirements are less stringent than those for quoting on AIM.
In accordance with Rule 23 of the Growth Market Rules, a NEX Exchange Corporate Adviser must submit the information no less than 10 business days prior to the intended admission date, and NEX Exchange will release the pre-admission announcement by RIS under the heading 'NEX Exchange' on the date of submission of the form.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
Incanthera announces Rule 23 Notice re NEX listing - RNS
Attachments
- Original document
- Permalink
Disclaimer
Immupharma plc published this content on 17 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2020 08:01:09 UTC
